HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tactica sale

This article was originally published in The Rose Sheet

Executive Summary

Helen of Troy sells its 55% ownership interest in Tactica International depilatory business to brand's current operating management, company announces April 30. Firm had announced plans to evaluate "strategic alternatives" for Tactica in October (1"The Rose Sheet" Oct. 6, 2003, p. 7) In light of the sale, Helen of Troy is revising its fiscal Q4 (ended Feb. 29) and year-end guidance. Fourth quarter net income from core business activities is expected to be approximately $16 mil., with an $8.5 mil.-$9.5 mil. loss attributed to Tactica operations. Consolidated net earnings, which will be announced May 13, are anticipated to be $6.5 mil.-$7.5 mil. Helen of Troy forecasts full-year consolidated net earnings of $59.2 mil.-$60.2 mil. and net income from the core business of $71 mil., with Tactica recording a $10.8 mil.-$11.8 mil. loss...

You may also be interested in...

Helen Of Troy Exploring Options For Tactica Depilatory Business

Helen of Troy is "evaluating strategic alternatives" for its investment in Tactica, the firm's depilatory products business, Chairman, President and CEO Gerald Rubin announced during a second quarter sales and earnings presentation Oct. 2

E.l.f. Puts Premium On ‘Clean Beauty’ With First Strategic Acquisition: W3ll People

W3ll People is expected to add a relatively modest $7m to e.l.f. Beauty’s fiscal 2021 top line, but the brand has “major white space” opportunities, including at Target, e.l.f.’s longest-standing customer. Further, its plant-based product line includes 40 “EWG Verified” products, reflecting expertise e.l.f. is eager to tap.

UCB Pins Growth Hopes On Burgeoning Late-Stage Pipeline

UCB's R&D efforts include late-stage diverse but complementary immunologicals and anti-neuroinflammatories.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts